Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.
2.

The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

Spillantini MG, Goedert M.

Ann N Y Acad Sci. 2000;920:16-27. Review.

PMID:
11193145
3.

Controversy: is Parkinson's disease a single disease entity? Yes.

Takahashi H, Wakabayashi K.

Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S31-7. Epub 2005 Apr 20. Review.

PMID:
15885626
4.

The cellular pathology of Parkinson's disease.

Takahashi H, Wakabayashi K.

Neuropathology. 2001 Dec;21(4):315-22. Review.

PMID:
11837539
5.

The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.

Wakabayashi K, Tanji K, Mori F, Takahashi H.

Neuropathology. 2007 Oct;27(5):494-506. Review.

PMID:
18018486
6.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
7.

Neuropathological spectrum of synucleinopathies.

Jellinger KA.

Mov Disord. 2003 Sep;18 Suppl 6:S2-12. Review.

PMID:
14502650
8.

Pathogenesis of Parkinson's disease.

Sherer TB, Betarbet R, Greenamyre JT.

Curr Opin Investig Drugs. 2001 May;2(5):657-62. Review.

PMID:
11569943
9.

[Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?].

Wakabayashi K.

Rinsho Shinkeigaku. 2008 Nov;48(11):981-3. Review. Japanese.

PMID:
19198138
10.

Alpha-synuclein, Abeta and Alzheimer's disease.

Wirths O, Bayer TA.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):103-8. Review.

PMID:
12551731
11.

[The mechanism of Lewy body formation in Parkinson's disease].

Wakabayashi K, Takahashi H.

Nihon Rinsho. 2000 Oct;58(10):2022-7. Review. Japanese.

PMID:
11068441
12.

Targeting alpha-synuclein for the treatment of Parkinson's disease.

Rohn TT.

CNS Neurol Disord Drug Targets. 2012 Mar;11(2):174-9. Review.

PMID:
22483285
13.
14.

Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders.

Ono K, Hirohata M, Yamada M.

Curr Pharm Des. 2008;14(30):3247-66. Review.

PMID:
19075704
15.

Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses.

Trojanowski JQ, Lee VM.

Neurotoxicology. 2002 Oct;23(4-5):457-60. Review.

PMID:
12428717
16.

Caught in the act: alpha-synuclein is the culprit in Parkinson's disease.

Eriksen JL, Dawson TM, Dickson DW, Petrucelli L.

Neuron. 2003 Oct 30;40(3):453-6. Review.

17.

Physiological and pathological properties of alpha-synuclein.

Tofaris GK, Spillantini MG.

Cell Mol Life Sci. 2007 Sep;64(17):2194-201. Review.

PMID:
17605001
18.

Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.

Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H.

Neuropharmacology. 2003 Jul;45(1):14-44. Review.

PMID:
12814657
19.

[Alpha-synuclein interacted proteins: the relevance with the pathogenesis of Parkinson's disease].

Xu F, Luo JH, Jin JH.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2008 Sep;37(5):524-30. Review. Chinese.

PMID:
18925724
20.

Supplemental Content

Support Center